Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322210 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322195 | 0.92 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322196 | 0.92 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322216 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322217 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322781 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322368 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322656 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL322657 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL321673 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | claimed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | claimed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | claimed |
| EP-2790705-B1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | claimed |
| US-9499536-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | claimed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2790705-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | Novartis AG (CH) | 2014-10-22 | — | — | EP | claimed |
| EP-2590974-B1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-21 | — | — | EP | claimed |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| US-8653092-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | claimed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | claimed |
| EP-2590974-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-05-15 | — | — | EP | claimed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | claimed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | claimed |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885 |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885 |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.